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BACKGROUND: Bevacizumab (Bev), a monoclonal antibody to vascular endothelial growth factor (VEGF), is used in combination with
chemotherapy for the treatment of metastatic colorectal cancer (CRC). The effects of Bev on angiogenesis have been well described,
but the direct effect of Bev on tumour cells is unknown. This study was carried out to determine the molecular and phenotypic
changes in CRC cells after chronic Bev exposure in vitro.
METHODS: Human CRC cell lines were chronically exposed (3 months) to Bev in vitro to develop Bev-adapted (Bev-A) cell lines.
Vascular endothelial growth factor family members were determined by reverse transcription–polymerase chain reaction and
western blotting. Migration and invasion was determined using standard in vitro assays. Intravenous injection of tumour cells was
carried out to evaluate metastatic potential in mice.
RESULTS: Bevacizumab-adapted cells were found to be more migratory and invasive than control cells (Po0.001). Bevacizumab-
adapted cells showed higher levels of VEGF-A, -B, -C, placental growth factor (PlGF), VEGF receptor-1 (VEGFR-1) and
phosphorylation of VEGFR-1. Furthermore, treatment with SU5416, a VEGFR protein tyrosine kinase inhibitor, led to significantly
decreased cell migration in vitro (Po0.001). Bevacizumab-adapted cells were more metastatic in vivo (Po0.05).
CONCLUSION: Chronic exposure of CRC cells to Bev (1) increased expression of VEGF-A, -B, -C, PlGF, VEGFR-1 and VEGFR-1
phosphorylation, (2) increased tumour cell migration and invasion, and (3) metastatic potential in vivo. Our study shows the functional
significance of autocrine VEGF signalling in CRC cells.
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Angiogenesis is a fundamental event in the process of tumour
growth and metastatic dissemination. The well-established role of
VEGF in promoting tumour angiogenesis and the pathogenesis of
human cancers has led to the development of therapeutic strategies
that selectively target this pathway. The FDA-approved anti-VEGF
antibody bevacizumab (Bev) is one such validated antiangiogenic
therapeutic agent that, when used in combination with chemother-
apy, has been shown to prolong survival in patients with metastatic
colorectal cancer (CRC) (Hurwitz et al, 2004). However, it has
become clear that virtually all patients, regardless of their tumour
type, will ultimately exhibit disease progression while on VEGF-
targeted therapy. Therefore, understanding the mechanisms by
which tumours adapt to VEGF blockade is important in optimising
therapeutic regimens utilising this approach.
The role of VEGF in the process of tumour angiogenesis, by
stimulation of vascular endothelial growth factor receptors
(VEGFRs) on the tumour endothelium, is well established
(reviewed in Hicklin and Ellis (2005) and Ferrara (2009)).
However, over the past decade, studies have shown that VEGFRs
are also present on numerous cell types, including haematopoietic
progenitor cells (Kaplan et al, 2005), cells of the central nervous
system (Poesen et al, 2008), immune mediator cells (Shin et al,
2009) and tumour cells themselves (Fan et al, 2005; Wey et al,
2005). Our laboratory has shown that VEGF can stimulate tumour
cell migration and invasion of CRC cells (Fan et al, 2005), and
these processes were thought to be mediated through VEGFR-1 as
a specific antibody (18F1) to VEGFR-1 blocked VEGF-mediated
responses (Fan et al, 2005). More recent studies from our
laboratory have focused on the role of the VEGF co-receptor,
neuropilin-2 (NRP-2), which mediates tumour cell survival path-
ways (Dallas et al, 2008). Thus, it has become increasingly clear
that tumour cells express VEGFRs, and thus it is possible that
some of the effects observed with anti-VEGF therapies are due to
direct effects on tumour cells.
As VEGFRs are present and functional on CRC cells, it is
possible that anti-VEGF therapy could inhibit processes mediated
by these receptors. On the other hand, it is also possible that, over
the long term, tumour cells could adapt (become resistant) to
the inhibition of VEGF signalling and therefore their phenotype
could be altered. As has been shown in mice and human beings,
administration of anti-VEGF therapy initiates compensatory
pathway activation, including upregulation of placental growth
Revised 2 February 2011; accepted 16 February 2011; published online
15 March 2011
*Correspondence: Professor LM Ellis; E-mail: lellis@mdanderson.org
British Journal of Cancer (2011) 104, 1270–1277
& 2011 Cancer Research UK All rights reserved 0007– 0920/11
www.bjcancer.com
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sfactor (PlGF) and stromal-derived factor-1 (SDF-1) (Batchelor
et al, 2007; Ebos et al, 2007; Folkins et al, 2009). In several
recent studies, investigators showed that in vivo administration of
VEGF-targeted therapies could lead to an increase in metastasis,
but the exact mechanism, and the cell types mediating this
mechanism, has yet to be identified (Ebos et al, 2009; Paez-Ribes
et al, 2009).
In this study, we investigated the molecular and phenotypic
changes associated with chronic exposure of CRC cells to Bev
in vitro. We found that chronic exposure of CRC cells to Bev leads
to increased migration and invasion in vitro that is associated
with increased expression of alternate VEGF family ligands, PlGF
and VEGF-C, and activation of VEGFR-1. Inhibition of activation
of VEGFRs blocked the increase in migration observed in Bev-
adapted cells. Bevacizumab-adapted cells exhibited an increase in
metastatic potential in vivo. These results provide new mechanistic
insights into the phenotypic alterations associated with Bev
adaptation of CRC cells. Studies such as these will help dissect
out the relative effects of chronic exposure of Bev on tumour cells,
elucidating the effect of VEGF inhibition on the numerous
individual components of the tumour microenvironment.
MATERIALS AND METHODS
Reagents and antibodies
Bevacizumab (Genentech BioOncology, South San Francisco, CA,
USA) was obtained from the pharmacy at MD Anderson Cancer
Center. SU5416 was purchased from Sigma-Aldrich (St Louis, MO,
USA). Antibodies for western blot analysis were as follows:
polyclonal goat anti-VEGF-A, polyclonal goat anti-VEGF-B167/186
(R&D Systems Inc., Minneapolis, MN, USA), rabbit anti-VEGF-C
(Zymed Laboratories, San Francisco, CA, USA), polyclonal rabbit
anti-PlGF (Abcam, Cambridge, MA, USA), polyclonal rabbit anti-
phospho-VEGFR-1 antibody (Millipore Corporation, Billerica, MA,
USA), polyclonal rabbit anti-Flt-1 (VEGFR-1), polyclonal rabbit
anti-Phospho-VEGFR-2 antibody and polyclonal rabbit anti-
VEGFR-2 (Cell Signaling, Danvers, MA, USA), polyclonal rabbit
anti-phospho-VEGFR-2 (Novus, Littleton, CO, USA), polyclonal
rabbit anti-VEGFR-3, NRP-1 and mouse monoclonal NRP-2,
Nonspecific mouse IgG (Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA).
Cell lines and culture conditions
HCT116 and SW480 human CRC cell lines were obtained from the
American Type Culture Collection (Manassas, VA, USA). Cell lines
were cultured in minimal essential medium (MEM) supplemented
with 5% foetal bovine serum (FBS), penicillin–streptomycin,
vitamins, sodium pyruvate, L-glutamine and non-essential amino
acids (Life Technologies, Grand Island, NY, USA) at 371Ci n5 %
CO2 and 95% air. Cells were confirmed to be free of mycoplasma
using the ‘MycoAlert’ Mycoplasma Detection Kit (Lonza Group,
Basel, Switzerland). Results from all in vitro studies were
confirmed in at least three independent experiments to verify
results. All the experiments were performed when cells reached
50–60% confluence.
Development of Bev-adapted CRC cells
The human CRC cell lines HCT116 and SW480 were exposed to a
clinically relevant dose of Bev (250mgml
 1) (Herbst et al, 2005) for
3 months in vitro to develop the Bev-adapted (Bev-A) cell lines
HCT116/Bev-A and SW480/Bev-A. HCT116 and SW480 cells were
also exposed to mouse IgG (250mgml
 1) in parallel to generate the
control cell lines HCT116/control and SW480/control.
Reverse transcription–polymerase chain reaction
Polymerase chain reaction (PCR) amplification of VEGFR-1,-2, -3,
NRP-1 and -2 was performed under the following conditions: 951C
for 5min, 27–40 cycles of 45s denaturing at 951C, 45s of annealing
at 571C and 1min of extension at 721C. Products were analysed by
electrophoresis of 20ml of each PCR reaction mixture in a 1.5%
agarose gel, and bands were visualised by ethidium bromide
staining. Human umbilical vein endothelial cells served as a
positive control. The following primers were used: VEGFR-1
(550bp, 40 cycles) – sense primer, 50-GACCTGGAGTTACCCTGA-30
and antisense primer, 50-GACACGGCCTTTTCGTA-30; VEGFR-2
primer (777bp, 40 cycles) – sense primer, 50-CTGGCGGCACGAAA
TATCCTCTTA-30 and antisense primer, 50-GGGCACCATTCCACC
AAAAGAT-30; VEGFR-3 (381bp, 40 cycles) – sense primer, 50-CCC
ACGCAGACATCAAGACG-30 and antisense primer, 50-TGCAGAA
CTCCACGATCACC-30; NRP-1 (450bp, 27 cycles) – sense primer,
50-ACGATGAATGTGGCGATACT-30 and antisense primer, 50-AGT
GCATTCAAGGCTGTTGG-30; NRP-2 (407bp, 30 cycles) – sense
primer, 50-ATTCGATGGTCCCGTTGG-30 and antisense primer,
50-ACCGTGCGGAGGTCGTTT-30; actin – sense primer, 50-GGAG
TACTTCCGCTCAGG-30 and antisense primer, 50-GCACTCTTC
CAGCCTTCCT-30.
Preparation of conditioned medium
Conditioned media were prepared as follows: cells were grown in
1% FBS–MEM for 72h, then CM was collected, centrifuged to
remove cell debris and concentrated about 20-fold (20  CM) by
using Centricon Centrifugal Filters (Millipore Corporation)
according to the manufacturer’s instructions.
Cell growth assay
The growth rate of control and Bev-A cells was evaluated with a
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT,
Sigma-Aldrich) assay. Cells were plated in 96-well plates at 2000
cells per well with MEMþ5% FBS with or without Bev, and cells
were incubated for 24, 48 or 72h. The MTT assay was carried out
according to the manufacturer’s protocol. Absorption was read at
570nm.
Western blot hybridisation
Cells were solubilised in 20mM Na-phosphate (pH 7.4), 150mM
NaCl, 1% Triton X-100, 1mM Na3VO4,5 m M EDTA and one
complete mini-protease inhibitor cocktail tablet (per 10ml of lysis
buffer; Roche Diagnostics, Indianapolis, IN, USA). Cell lysates
were then separated on 8% sodium dodecyl sulphate–polyacryl-
amide gels and transferred to polyvinylidene difluoride mem-
branes (Amersham, Arlington Heights, IL, USA). Membranes were
probed with primary antibodies overnight at 41C, and the next day,
they were washed thrice for 10min with TBS and 0.1% Tween-20
and re-probed with the appropriate secondary antibody for 1h at
room temperature. After incubation and three washes, immuno-
stained proteins were detected by Pierce ECL Western Blotting
Substrate (Thermo Scientific, Rockford, IL, USA). Human
umbilical vein endothelial cells served as a positive control.
Vinculin served as a protein loading control.
VEGFR inhibition studies
1 10
6 control or Bev-A cells were plated in a 10cm dish in
MEMþ5% FBS and allowed to attach overnight. The medium was
then replaced with MEMþ5% FBS with or without SU5416 (5mM)
for 48h. Whole-cell lysates were prepared, and total and
phosphorylation of VEGFR-1 were assessed by western blot
analysis. SU5416 was dissolved in DMSO.
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Migration assay was conducted as described previously (Dallas
et al, 2008) with minor modifications. Equal numbers (125000
cells per well) of control or Bev-A cells were suspended in 0.5ml of
1% MEM–FBS with or without Bev and placed in the top
compartment of a standard 8-mm-pore Boyden chamber; 0.750ml
of 10% MEM–FBS with or without Bev was added to the bottom
compartment. Following 48-h incubation under standard condi-
tions (371C/5% CO2), non-migrating cells were scraped from the
top compartment, and cells that had migrated to the bottom
compartment were fixed and stained using the Protocol HEMA 3
stain set (Thermo Fisher Scientific, Pittsburgh, PA, USA).
Membranes were excised and mounted on a standard microscope
slide (Curtis Matheson Scientific, Houston, TX, USA). The numbers
of migrated cells were determined from five random high-power
fields visualised at  200 magnification.
Invasion assays used identical methods, except that the cells were
placed in the top compartment of a modified Boyden chamber on a
Matrigel-coated membrane. The numbers of invasive cells were
determined from five random fields visualised at  200 magnification.
Scratch wound-healing/migration assay
The scratch assay was used to further evaluate the difference in
migration between the control and Bev-A cell lines. Cell lines were
grown in 10-cm plates, and when cells were 90% confluent,
scratches were made on the plates using a sterile 200-ml pipette tip.
The plates were then carefully washed twice with phosphate-
buffered saline. Fresh culture medium supplemented with 5% FBS
with or without Bev was gently added onto the plates. The plates
were allowed to incubate over the next 1–2 days. Photographs
were taken at regular intervals to monitor closure of the gap.
Image J 1.43u/Java 1.6.0_10 (32-bit) analysis software from the
NIH is used to quantify the results of wound closure.
In vivo metastasis study
To evaluate the metastatic potential of Bev-A cells, HCT116/control
and HCT116/Bev-A cells were stably infected with a luciferase
reporter gene lentiviral construct. A total of 1.5 10
6 luciferase-
labelled cells were suspended in 100ml of HBSS and injected
intravenously via the tail vein. The incidence and volume of
metastasis was estimated by serially imaging mice for biolumines-
cence using the IVIS 100 imaging system coupled to a data-
acquisition personal computer equipped with the Living Image
software (Xenogen, Hopkinton, MA, USA). The mice were
anaesthetised with a 1.5% isoflurane–oxygen mixture and injected
intraperitoneally with luciferase potassium salt solution (Sigma-
Aldrich) at a dose of 150mgkg
 1 body weight, waiting for 10min
before imaging. The photon emission (representative of luciferase
activity) was used to assess relative tumour burden in the mice.
Statistical analyses
For the in vitro studies, statistical analyses were carried out using
the Student’s t-test. For the in vivo studies, statistical significance
was determined by using the Fisher’s exact test (comparison of
incidence) or Mann–Whitney U-test (comparison of means), as
indicated. All statistical tests were two-sided, and P-values o0.05
were considered to be statistically significant.
RESULTS
Chronic Bev exposure increased VEGF family members
To study the effects of chronic Bev exposure on VEGF family
members in CRC cells, the expression of VEGFRs and ligands were
determined by reverse transcription (RT)–PCR and western
blotting in control (IgG) and Bev-A cell lines. Both HCT116/Bev-A
and SW480/Bev-A cell lines showed increased VEGFR-1, -3 and
NRP-1 expression compared with the respective control cells by
RT–PCR (Figures 1A and B). Vascular endothelial growth factor
receptor-2 levels did not change in HCT116 cells and was
undetectable in SW480 cells. Neuropilin-2 did not change in both
of HCT116 and SW480 cell lines. These findings were further
studied at the protein level by western blot analysis. Both HCT116/
Bev-A and SW480/Bev-A cell lines showed increased expression
of total and phospho-VEGFR-1. Neuropilin-1 protein level was
increased in SW480/Bev-A cells only. The levels of total VEGFR-3
and NRP-2 protein expression remained unchanged in both cell
lines (Figures 1C and D). There was no difference in VEGFR-2
phosphorylation and total level of protein expression in HCT116
cells (data not shown). Conditioned medium was collected from
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Figure 1 Effect of chronic bevacizumab exposure on CRC cells VEGF
family profile. (A and B) RT–PCR shows that cells under Bev treatment
have increased VEGFR-1, -3 and NRP-1 expression in both HCT116 and
SW480 cells. (C and D) Western blot confirmed that in both HCT116 and
SW480 cells, chronic bevacizumab exposure increased phosphorylation
and total level of VEGFR-1 expression. Vascular endothelial growth factor
receptor-3 and NRP-1, -2 remained unchanged in HCT116 cells.
Neuropilin-1 was increased and VEGFR-3 and NRP-2 remained unchanged
in SW480 cells. (E and F) Conditioned medium was collected and western
blot performed in both HCT116 and SW480 cell. Cells under bevacizumab
exposure had increased VEGF-A, -C and PlGF expression. Vascular
endothelial growth factor-B was increased in HCT116 cells and remained
unchanged in SW480 cells.
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sthe cells and western blots were carried out to determine levels of
VEGF family ligands. Both HCT116/Bev-A and SW480/Bev-A cell
lines showed significantly increased VEGF-A, -C and PlGF protein
levels. Ponceau S served as loading control. Vascular endothelial
growth factor-B was increased in HCT116/Bev-A cells and
remained unchanged in SW480 cells (Figures 1E and F).
Chronic Bev exposure enhances CRC cell migration
To study the effects of chronic Bev exposure on cell migration,
control and Bev-A CRC cells were seeded in a modified Boyden
chamber with or without Bev, and migration was assessed 48h
later. Both HCT116/Bev-A and SW480/Bev-A cell lines showed a
three- or two-fold increase in migration compared with the
respective control cells (Figure 2A, Po0.001 vs control; Figure 2B,
Po0.0001 vs control). Both HCT116/Bev-A and SW480/Bev-A cell
lines exhibited growth rates similar to those of their respective
controls, as determined by MTT assay (data not shown). To further
confirm the result from the Boyden chamber assay, motility of the
Bev-A cells was assessed by the scratch assay (wound healing
assay). In the scratch assay, the Bev-A cells migrated inwardly and
covered a greater area of the scratch at 48h than did control cells.
Similar results were observed for both HCT116/Bev-A and SW480/
Bev-A cells (Figures 2C and D). (HCT116/Bev-A 76% vs HCT116/
control 43%; SW480/Bev-A 80% vs SW480/control 29%).
Chronic Bev exposure enhances CRC cell invasion
Next, the Bev-A cells were evaluated for their invasive capabilities.
In Matrigel invasion assays, both HCT116/Bev-A and SW480/Bev-A
cells showed increased invasion (three- to four-fold) compared
with the respective control cells (Figure 3A, Po0.01 vs control;
Figure 3B, Po0.0004 vs control).
SU5416 inhibited CRC cell migration
To test the effect of inhibition of VEGFR-1 activation on cell
migration, motility of the Bev-A cells was assessed by the scratch
assay in the presence or absence of SU5416. As above, both
HCT116/Bev-A and SW480/Bev-A cells migrated inwardly and
covered a greater area of the defect than did control cells (HCT116/
Bev-A 91% vs HCT116/control 60%; SW480/Bev-A 87% vs SW480/
control 50%). Treatment with SU5416 blocked cell migration
(Figures 4A and D) (HCT116/Bev-AþSU5416 58% vs HCT116/Bev
91%; SW480/Bev-AþSU5416 43% vs SW480/Bev-A 87%). To
further confirm the result from the scratch assay. HCT116/Bev-A
and SW480/Bev-A cells were pretreated with or without SU5416
(5mM) for 4h, cells were then trypsinised and seeded in a modified
Boyden chamber with or without SU5416 for 48h. As above, both
HCT116/Bev-A and SW480/Bev-A cell lines showed a two- to
three-fold increase in migration compared with the respective
control cells (Po0.0002 vs control; Po0.001 vs control, respec-
tively). The Bev-A cells treated with SU5416 showed decreased
migration compared with solvent alone (Figures 4B and E,
Po0.000004 vs HCT116/Bev-AþDMSO; Po0.001 vs SW480/Bev-A
þDMSO). Both HCT116/Bev-A and SW480/Bev-A cell lines exhibited
growth rates similar to those of their respective controls, as
determined by MTT assay (data not shown). Chronic exposure to
Bev led to an increase in the level of phosphorylated VEGFR-1
in the both of HCT116/Bev-A and SW480/Bev-A cells. Treatment
of HCT116/Bev-A and SW480/Bev-A cells with SU5416 led to
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Figure 2 Effect of chronic bevacizumab exposure on CRC cell migration. (A and B) Using Boyden chamber migration assays, both HCT116/Bev-A
(A) and SW480/Bev-A (B) cells showed a two- to three-fold increase in migration compared with that of control cells (Po0.001, Po0.0001, respectively).
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by western blotting (Figures 4C and F).
Bev-A cells increased metastatic potential in vivo
Because migration and invasion are theoretically associated with
the metastatic phenotype, luciferase labelled HCT116/control and
HCT116/Bev-A cells were injected into the tail vein of athymic
nude mice. At the end of 6 weeks, all mice were killed. The mice
injected with HCT116/Bev-A cells had a higher incidence of meta-
stasis than that in mice injected with control cells (10 out of 12
Bev vs 4 out of 11 control, Po0.05). Mice injected with HCT116/
Bev-A cells showed significantly higher luciferase activity (B10-
fold higher) compared with the mice injected with control cells
(Po0.005, Figure 5A, upper panel). Imaging of the whole animal
and harvested organs revealed that luciferase activity was higher in
almost every organ harvested in mice injected with the HCT116/
Bev-A cells (Figure 5A, lower panel). All mice underwent a detailed
necropsy and all masses were removed to calculate the average
number of metastases. There was a significant increase in the total
number of metastases in the Bev-A group compared with the
control group (Figure 5B, Po0.02). In addition, there was a
significant increase in total tumour burden in the Bev-A group as
assessed by adding the volume of each metastasis for each mouse
in each group (Figure 5C, Po0.01).
DISCUSSION
Despite the proven clinical benefit of the VEGF monoclonal
antibody Bev (with chemotherapy) in prolonging progression-free
survival of patients with metastatic CRC, the benefit of therapy is
short-lived (B1–4 months), and the vast majority of patients
eventually progress (Hurwitz et al, 2004; Giantonio et al, 2007;
Saltz et al, 2008). Preclinical studies and clinical observations have
now begun to shed light on the mechanisms of action of anti-VEGF
therapy and acquired resistance (reviewed in Bergers and Hanahan
(2008) and Ellis and Hicklin (2008, 2009)).
Owing to the role of VEGF in mediating multiple components of
the tumour microenvironment, mechanisms of acquired resistance
are complex and multi-factorial. For example, Ebos et al (2007)
showed that administration of a VEGFR tyrosine kinase inhibitor
to non-tumour-bearing mice led to an increase in levels of
circulating cytokines such as granulocyte colony-stimulating
factor, SDF-1a, stem cell factor and osteopontin. This result shows
the role of adaptation of the host vasculature in response to
blockade of VEGF signalling. Recently, several publications have
reported that VEGFR blockade can lead to an increase in tumour
invasion and metastasis (Ebos et al, 2009; Paez-Ribes et al, 2009).
These publications raised a great deal of interest and concern in
the oncology community, as four VEGF-targeted agents are now
approved for use in the United States in patients with advanced-
stage or metastatic malignancies. The mechanism for these
observations remains to be elucidated, but it has been hypothe-
sised that the adaptive response to blockade of VEGF signalling
leads to a compensatory increase in cytokines that may increase
tumour aggressiveness (Ellis and Hicklin, 2009). However, it is
important to point out that these investigators utilised single-agent
VEGF-targeted therapies, without the addition of chemotherapy.
Chemotherapy, in and of itself, can lead to alterations in cytokine
signalling (Fan et al, 2008), making preclinical modelling of
clinical disease a challenge (Ellis and Fidler, 2010). Sorting out the
effects of VEGF inhibition on the tumour microenvironment poses
challenges because multiple cell types within the tumour micro-
environment express VEGFRs. These cell types include endothelial
cells, pericytes, immune effector cells and tumour cells themselves.
One approach to understanding the contributions of individual
cellular components of the tumour is to create VEGF-resistant/
adapted cells in vitro, and study their phenotype in vivo. In our
studies, we focused on the direct effects of Bev adaptation on CRC
cells, in contrast to other studies that have focused entirely on
endothelial cells.
Our studies showed that CRC cells exposed to Bev in vitro
showed marked molecular and phenotypic changes. Bevacizumab
adaptation resulted in increased migration at 1 week, 1 month, 2
months (data not shown) and 3 months (the time point used for all
studies shown in this manuscript) and invasion of human CRC cell
lines in vitro; however, proliferation remained unaffected. As
expected, the increase in invasion and migration of Bev-adapted
cells led to an increase in in vivo metastatic potential. We found no
morphological evidence of EMT by molecular markers or
morphological alterations. As many studies have shown that
blockade of VEGF signalling in vivo leads to compensatory
increases in the expression of VEGF family members, we
investigated alterations in the VEGF family of ligands. We also
investigated changes in VEGFR level and activation on tumour
cells, as we have previously shown that VEGFRs are present and
functional on tumour cells. Our studies showed that blockade of
autocrine VEGF signalling in tumour cells led to induction of
VEGF and other VEGF family members. We found a marked
induction of VEGFR-1 levels and activation of VEGFR-1, whereas
there were no changes in VEGFR-3 levels; VEGFR-2 levels and
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sphosphorylation status did not change in HCT116 cells and was
undetectable in SW480 cells (and therefore the increased levels of
VEGF-C would not effect VEGFR-2 activation in SW480 cells). As
VEGFR-1 was activated (likely due to the observed induction of
PlGF and VEGF-B, two VEGF family members that bind to
VEGFR-1), we sought to determine if the increase in VEGFR-1
activation mediated the increase in migration. Previously, we have
shown that VEGFR-1 activation mediates migration in CRC cells
(Fan et al, 2005). The tyrosine kinase inhibitor SU5416 primarily
inhibits activation of the VEGF tyrosine kinase receptors, with
some activity to other related kinases including Kit and Ret (Fong
et al, 1999). SU5416 blocked the induction of VEGFR-1 observed in
Bev-adapted cells and likewise inhibited the increase in migration
observed in these cells. Cumulatively, the above studies show that
CRC cells exhibit autocrine VEGF/VEGFR signalling and inhibition
of VEGF signalling leads to compensatory pathways mediated via
VEGFR-1 activation that lead to increased migration and invasion.
This observed increase in tumour cell invasion, migration and
metastasis with VEGF signalling inhibition is intriguing consider-
ing the recent work of others suggesting that VEGF inhibition in
mice can increase metastasis (Casanovas et al, 2005; Ebos et al,
2009). However, it is important to consider these studies in light of
results from several clinical trials in CRC. In the clinic, patients
with metastatic CRC are treated with Bev in combination with
chemotherapy, but Bev is not approved for use as a single agent in
the United States. No study has show an increase in rates of
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smetastasis in patients with metastatic CRC treated with Bev and
chemotherapy (Ellis and Reardon, 2010). However, a few clinical
studies have examined the use of Bev as a single agent in metastatic
CRC, and the one study conducted with single-agent Bev in such
patients did not specifically investigate sites of metastasis or
reasons for disease progression (Giantonio et al, 2007). However,
there are now two completed Phase III trials studying the use
of Bev and chemotherapy in the adjuvant setting in patients
with stage 2 and 3 cancer. Both trials had a similar trial design:
chemotherapy alone vs chemotherapy and Bev for B6 months,
followed by single-agent Bev for 6 months. The first trial, National
Surgical Adjuvant Breast and Bowel Project CO-8, was recently
published (Allegra et al, 2011). In this study, there was no benefit
to patients who received Bev in addition to chemotherapy, as
disease-free survival was the same for both groups at 3 years. In
the AVANT trial, there was likewise no benefit when Bev was
added to chemotherapy, and interestingly, patients who received
chemotherapy alone appeared to have a better outcome than those
patients who received chemotherapy and Bev (de Gramont et al,
2011). In both studies, the per cent of patients who recurred at
multiple sites of metastasis was similar. However, in light of the
AVANT trial outcome where the patients who received Bev seemed
to have a shorter disease-free survival, one must scrutinise the
results of other clinical trials in the adjuvant setting where single-
agent VEGF-targeted therapies are utilised. It is clear that the effect
of VEGF-targeted therapy in the adjuvant setting is not the same as
when used in patients with documented metastatic CRC.
Our studies showing that in vitro Bev adaptation led to an
increase in tumour aggressiveness in vitro show two important
findings. The first is that VEGFRs are present and functional on
CRC cells, as blockade leads to a phenotypic change. The second is
that blockade of VEGF signalling as a single agent in CRC cells can
possibly lead to an increase in tumour cell aggressiveness.
Therefore, the use of single-agent Bev in patients with CRC should
not be considered outside of a clinical trial setting.
In conclusion, chronic blockade of VEGF signalling in CRC by
Bev leads to an increase in cell migration and invasion in vitro, and
metastasis in vivo. These findings may explain, in part, the studies
by others showing that VEGF blockade in vivo leads to an increase
in metastatic potential. On the basis of these studies and clinical
trial results, there is no justification at this time to use single-agent
Bev in patients with metastatic CRC. However, these studies
were carried out with single-agent Bev and do not take into account
the complexities of combining Bev with chemotherapy in vivo.
Interestingly, the in vitro increase in tumour cell migration and
invasion in Bev-A cells was abrogated by VEGFR1 inhibition,
suggesting that perhaps this combination should be further explored
in preclinical studies and, if appropriate, in clinical studies.
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